Exelixis reported $515.2M in net product revenues in Q4'24, a 20% increase over net product revenues for Q4'23. See why I ...
AnaptysBio (ANAB) stock climbs as its antibody therapy rosnilimab meets key goals in mid-stage rheumatoid arthritis trial, ...
Hosted on MSN18h
Trump’s tariffs will trickle down the clinical trial chainTariffs will not only impact sponsors, but higher costs will ripple down the clinical trial supply chain in the US.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback